31 studies found for:    Benign Essential Blepharospasm
Show Display Options
Rank Status Study
21 Completed Mexiletine for the Treatment of Focal Dystonia
Conditions: Blepharospasm;   Dystonia;   Spasm
Intervention: Drug: Mexiletine
22 Completed Movement Disorder Survey in East China
Conditions: Primary Dystonia;   Hemifacial Spasm
Intervention:
23 Completed Post Marketing Surveillance Study of Dysport
Conditions: Blepharospasm;   Hemifacial Spasm;   Cervical Dystonia;   Spasmodic Torticollis;   Cerebral Palsy;   Muscle Spasticity;   Cerebrovascular Accident;   Equinus Deformity;   Facial Hyperdynamic Lines
Intervention:
24 Completed Cognitive Function and Emotional Possessing in Bilateral Facial Palsy
Conditions: Intelligence;   Emotion
Intervention:
25 Completed Efficacy of Aurosling in Frontalis Sling Suspension Surgery
Condition: Ptosis, Eyelid
Intervention: Procedure: Aurosling
26 Completed Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives
Condition: Dystonia
Intervention:
27 Active, not recruiting Deep Brain Stimulation in Patients With Dystonia
Condition: Dystonia
Intervention: Device: Medtronic implantable deep brain stimulation (DBS) system
28 Recruiting Dystonia Coalition Projects
Conditions: Dystonia;   Voice Disorders
Intervention:
29 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
30 Completed
Has Results
Botulinum Toxin in the Treatment of Raynaud's
Condition: Raynaud's Syndrome
Intervention: Drug: botulinum toxin A
31 Not yet recruiting Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis
Condition: Plantar Fasciitis
Interventions: Drug: Botulinum toxin A;   Drug: cortisone;   Drug: Saline

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-31) Next Page   
Indicates status has not been verified in more than two years